MARKET

ARRY

Array Biopharma
ARRY
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
66.95
3.963
-45.3846
3,671,410,040.97
Solar stocks on fire amid Biden climate plans; SolarEdge upgraded at Barclays
Solar stocks including Enphase Energy ([[ENPH]] +7.2%) and SunPower ([[SPWR]] +5.1%) post strong gains, buoyed by President Biden's ambitious new emission reduction proposals ahead of this week's climate summit of
Seekingalpha · 22h ago
DJ Array Technologies Raised to Overweight From Equal-Weight by Barclays
Dow Jones · 1d ago
DJ Array Technologies Price Target Cut to $32.00/Share From $40.00 by Barclays
Dow Jones · 1d ago
Barclays Upgrades Array Technologies to Overweight From Equal-Weight, Adjusts Price Target to $32 From $40
MT Newswires · 1d ago
FTC Solar expects IPO to price at $18-$20 a share, valuing firm at some $1.6B
Green-power equipment firm FTC Solar (FTCI) released specifics Monday for a previously announced IPO, disclosing plans to sell some 18.4M shares that it expects to price between $18 and $20
Seekingalpha · 3d ago
Analyst Actions: UBS Upgrades Array Technologies to Buy From Neutral, Citing 'Solid US Utility-Scale Solar Demand;' Maintains $43 Price Target
MT Newswires · 04/16 10:41
DJ Array Technologies Raised to Buy From Neutral by UBS
Dow Jones · 04/16 10:17
DJ Array Technologies Price Target Announced at $43.00/Share by UBS
Dow Jones · 04/16 10:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARRY. Analyze the recent business situations of Array Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARRY stock price target is 44.29 with a high estimate of 48.00 and a low estimate of 32.00.
EPS
Institutional Holdings
Institutions: 282
Institutional Holdings: 225.98M
% Owned: 101.91%
Shares Outstanding: 126.99M
TypeInstitutionsShares
Increased
101
22.89M
New
62
16.02M
Decreased
74
24.33M
Sold Out
27
2.55M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Renewable Energy Equipment & Services
+2.78%
Renewable Energy
+2.54%
Key Executives
Chairman/Independent Director
Carrie Cox
President
John Wattsun
Chief Executive Officer/Director
Ron Squarer
Chief Financial Officer
Jason Haddock
Chief Operating Officer
Andrew Robbins
Chief Scientific Officer
Nicholas Saccomano
General Counsel
Rogan Nunn
Other
Victor Sandor
Independent Director
Charles Baum
Independent Director
Gwendolyn Fyfe
Independent Director
Kyle Lefkoff
Independent Director
John Orwin
Independent Director
Shalini Sharp
Independent Director
Gil Van Lunsen
No Data
  • All
  • Financials
  • Insiders
More

Webull offers kinds of Array Biopharma stock information, including NASDAQ:ARRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARRY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARRY stock methods without spending real money on the virtual paper trading platform.